Benzimidazoles and pharmaceutical preparations containing these compounds
    7.
    发明授权
    Benzimidazoles and pharmaceutical preparations containing these compounds 失效
    苯并咪唑和含有这些化合物的药物制剂

    公开(公告)号:US5039675A

    公开(公告)日:1991-08-13

    申请号:US497223

    申请日:1990-03-22

    CPC分类号: C07D403/04

    摘要: New benzimidazoles correponding to the general formula I ##STR1## are described, in which the pyridazinone ring is attached in the 5- or 6- position of the benzimidazole ring and R.sup.1 denotes a hydrogen atom or a straight chained or branched C.sub.1 to C.sub.4 alkyl group, R.sup.2 denotes a hydrogen atom, a straight chained or branched C.sub.1 to C.sub.4 alkyl group, a C.sub.1 to C.sub.4 alkoxy group, a hydroxy group, a halogen atom, an amino group or a nitro group, A denotes a hydrogen atom, a group of the formula ##STR2## wherein R.sup.3 denotes a hydrogen atom, an optionally substituted C.sub.1 to C.sub.4 alkyl group or a C.sub.1 to C.sub.4 alkoxy group and B denotes a cyano group, a benzoyl group or a phenylsulphonyl group, or A denotes a group of the formula ##STR3## in which m has the value 2 or 3 and n represents an integer from 1 to 6, and the physiologically acceptable salts thereof as well as processes for their preparation and pharmaceutical preparations. containing these compounds These compounds are new, effective, positive inotropic substances which do not act by the mechanism of phosphodiesterase inhibition.

    Benzimidazoles, and pharmaceutical preparations containing these
compounds
    8.
    发明授权
    Benzimidazoles, and pharmaceutical preparations containing these compounds 失效
    苯并咪唑和含有这些化合物的药物制剂

    公开(公告)号:US4957920A

    公开(公告)日:1990-09-18

    申请号:US168273

    申请日:1988-03-15

    CPC分类号: C07D403/04

    摘要: New benzimidazoles corresponding to the general formula I ##STR1## are described, in which the pyridazinone ring is attached in the 5- or 6- position of the benzimidazole ring and R.sup.1 denotes a hydrogen atom or a straight chained or branched C.sub.1 to C.sub.4 alkyl group, R.sup.2 denotes a hydrogen atom, a straight chained or branched C.sub.1 to C.sub.4 alkyl group, a C.sub.1 to C.sub.4 alkoxy group, a hydroxy group, a halogen atom, an amino group or a nitro group, A denotes a hydrogen atom, a group of the formula ##STR2## wherein R.sup.3 denotes a hydrogen atom, an optionally substituted C.sub.1 to C.sub.4 alkyl group or a C.sub.1 to C.sub.4 alkoxy group and B denotes a cyano group, a benzoyl group or a phenylsulphonyl group, or A denotes a group of the formula ##STR3## in which m has the value of 2 or 3 and n represents an integer from 1 to 6, and the physiologically acceptable salts thereof as well as processes for their preparation and pharmaceutical preparations containing these compounds. These compounds are new, effective, positive inotropic substances which do not act by the mechanism of phosphodiesterase inhibition.

    摘要翻译: 描述了对应于通式I(I)的新的苯并咪唑,其中哒嗪酮环连接在苯并咪唑环的5-或6-位,R1表示氢原子或直链或支链C1至 C4烷基,R2表示氢原子,直链或支链C1〜C4烷基,C1〜C4烷氧基,羟基,卤素原子,氨基或硝基,A表示氢原子, 式中,R 3表示氢原子,可以具有取代基的C1〜C4烷基或C1〜C4烷氧基,B表示氰基,苯甲酰基或苯基磺酰基,A表示基团 其中m具有2或3的数值,n表示1至6的整数,以及其生理上可接受的盐以及其制备方法和含有这些化合物的药物制剂。 这些化合物是新的,有效的正性肌力物质,不受磷酸二酯酶抑制机制的作用。